Implementation of prophylactic HPV vaccination: Progress and future challenges

Loretta Brabin, Henry C. Kitchener, Peter L. Stern

    Research output: Contribution to journalArticlepeer-review


    Two licensed vaccines designed to prevent certain human papillomavirus (HPV) infections are currently available. Their use to prevent cervical cancer has depended on data from clinical trials of safety, immunogenicity and efficacy in preventing surrogate end points of cancer. Following these pivotal studies, HPV vaccines are being introduced into national vaccination programs, mostly in developed countries, and are largely targeting girls 10-14 years of age, with a one-time catch-up opportunity for older teens. Some countries have achieved a level of coverage that is consistent with economic models predicting their cost-effectiveness. At the same time, clinical trials among males and older women have led to pressure to expand the population groups offered HPV vaccination. Over the next 5 years, health authorities will need to make clear decisions about how best to deploy HPV vaccines, as well as to increase or maintain high coverage among young adolescent girls. © 2010 Expert Reviews Ltd.
    Original languageEnglish
    Pages (from-to)591-603
    Number of pages12
    JournalExpert Review of Obstetrics and Gynecology
    Issue number5
    Publication statusPublished - Sept 2010


    • adolescent girls
    • cervical cancer
    • HPV vaccine programs
    • HPV vaccine uptake
    • human papillomavirus vaccine
    • males
    • older women


    Dive into the research topics of 'Implementation of prophylactic HPV vaccination: Progress and future challenges'. Together they form a unique fingerprint.

    Cite this